vaccin
consid
one
cost
effect
medic
intervent
contribut
significantli
improv
public
health
last
centuri
variou
type
vaccin
develop
erad
infecti
diseas
kill
million
peopl
vaccin
weaken
alter
inactiv
vaccin
toxin
gener
bacteria
bacteria
subunit
conjug
vaccin
segment
pathogen
current
eighti
vaccin
licens
use
unit
state
viral
vaccin
also
fda
approv
sever
vaccin
candid
develop
http
effort
ongo
improv
exist
vaccin
develop
novel
vaccin
target
infecti
diseas
high
unmet
medic
need
global
public
health
commun
goal
develop
prevent
therapeut
vaccin
major
diseas
target
human
immunodefici
viru
hiv
ebola
zika
chikungunya
middl
east
respiratori
syndrom
coronaviru
sever
acut
respiratori
syndrom
sar
west
nile
lyme
diseas
lassa
fever
yellow
fever
nipah
viru
respiratori
syncyti
viru
rsv
influenza
dengu
unfortun
despit
increas
understand
immunolog
greater
insight
virus
respons
infect
limit
success
achiev
toward
develop
vaccin
epidem
target
popul
vaccin
healthi
individu
pregnant
women
infant
vaccin
safeti
paramount
import
appropri
vaccin
landscap
chang
tradit
vaccin
approach
highli
scalabl
safe
recombin
use
recombin
dna
technolog
antigen
express
yeast
escherichia
coli
baculoviru
express
vector
system
bev
mammalian
cell
recombin
antigen
engin
mimic
first
step
viru
attach
cell
surfac
mediat
specif
glycoprotein
express
recombin
antigen
undergo
multipl
purif
cycl
produc
highli
purifi
order
recombin
vaccin
accept
regulatori
author
analyt
character
need
perform
clinic
trial
materi
ctm
ensur
vaccin
safe
effect
qualiti
control
qc
analyt
test
routin
perform
clinic
trial
materi
batch
releas
certifi
content
test
perform
either
high
perform
liquid
chromatographi
uvvi
spectrophotomet
measur
absorb
nm
solovp
newest
evolut
spectroscopi
puriti
test
perform
either
size
exclus
chromatographi
sec
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
capillari
electrophoresi
sodium
dodecyl
sulfat
capillari
isoelectr
focus
cief
residu
impur
test
perform
immunosorb
assay
elisa
host
cell
protein
quantit
polymeras
chain
reaction
qpcr
host
cell
dna
etc
within
product
specif
ensur
potenc
test
perform
elisa
ligand
free
bind
assay
biolay
interferometri
bli
surfac
plasmon
reson
spr
safeti
microbi
enumer
test
endotoxin
test
etc
vaccin
candid
per
ich
harmonis
tripartit
guidelin
http
wwwichorg
anoth
regulatori
prerequisit
perform
extens
physiochem
character
recombin
antigen
mass
spectrometri
method
choic
perform
comprehens
physiochem
character
glycoprotein
mass
character
critic
standpoint
understand
product
structur
also
help
establish
clinic
trial
materi
releas
specif
ensur
qualiti
figur
thu
innov
vaccin
structur
design
follow
comprehens
analyt
character
requir
success
develop
novel
vaccin
epidem
infecti
diseas
impact
larg
segment
global
popul
review
focu
expand
role
mass
spectrometri
vaccin
develop
irrespect
rout
product
also
highlight
regulatori
challeng
limit
mass
techniqu
constrain
implement
qualiti
control
batch
releas
assay
cgmp
manufactur
quest
safe
effect
vaccin
protect
human
immunodefici
viru
type
infect
even
thirti
five
year
hiv
epidem
vaccin
approach
licensur
estim
million
peopl
global
live
hiv
approxim
million
new
infect
diagnos
despit
major
advanc
antiretrovir
therapi
art
inspir
global
commit
requir
end
epidem
http
wwwunaidsorgenresourcesfactsheet
unfortun
develop
effect
vaccin
challeng
reason
relat
natur
sever
vaccin
concept
test
efficaci
trial
one
pox
viru
prime
protein
boost
alvacaidsvax
vaccin
show
low
level
vaccin
protect
estim
vaccin
one
hypothes
explor
protect
immun
hiv
induc
broadli
neutral
antibodi
bnab
target
highli
glycosyl
number
approach
pursu
vaccin
develop
field
establish
protect
immun
includ
monomer
subunit
oligomer
trimer
envelop
glycoprotein
elicit
envelop
env
immunogen
multipl
expos
epitop
heterogen
glycosyl
molecul
mass
consist
glycan
glycan
critic
import
monitor
hiv
env
glycan
shield
vaccin
number
method
avail
perform
glycan
character
liquid
chromatographi
hilic
conjunct
posit
neg
ion
mode
ms
routin
use
method
glycan
profil
use
multistag
fragment
techniqu
collis
induc
dissoci
cid
electron
transfer
dissoci
etd
analysi
proteolyt
digest
glycoprotein
commonli
use
method
determin
site
glycosyl
first
studi
analyz
glycosyl
recombin
express
cho
cell
perform
fraction
tryptic
digest
revers
phase
hplc
peptid
fraction
amino
acid
sequenc
subsequ
identifi
amino
acid
analysi
aaa
extens
analysi
env
immunogen
use
method
carri
desair
collabor
last
decad
group
demonstr
broadli
applic
method
analyz
glycosyl
disulfid
map
hiv
env
protein
develop
method
success
use
analyz
multipl
immunogen
monom
oligom
trimer
nativ
trimer
ms
experi
conduct
result
report
desari
collabor
significantli
contribut
advanc
develop
hiv
recent
go
et
al
use
approach
map
complet
glycosyl
profil
everi
site
eleven
trimer
env
accomplish
two
goal
determin
glycosyl
site
contain
conserv
glycan
profil
across
differ
trimer
env
ii
identifi
variabl
impact
env
glycosyl
profil
site
diverg
glycosyl
studi
conclud
process
mani
glycosyl
site
recombin
env
affect
express
crispin
collabor
also
extens
investig
nativ
glycosyl
profil
env
particularli
trimer
immunogen
studi
led
increas
understand
glycan
shield
env
larg
accept
induc
bnab
hiv
vaccin
candid
glycan
profil
similar
one
present
nativ
env
thorough
studi
trimer
env
glycosyl
behren
et
employ
parallel
approach
exploit
ms
analyz
glycosyl
solubl
recombin
trimer
result
identif
separ
set
studi
harvey
et
al
util
ion
mobil
mass
techniqu
analyz
env
glycosyl
figur
abil
ion
mobil
separ
isomer
glycan
util
profil
complex
type
isom
trimer
recent
paulson
collabor
report
analysi
six
differ
strain
hiv
env
glycoprotein
present
gener
ms
proteom
strategi
use
specif
endoglycosidas
introduc
mass
signatur
distinguish
glycopeptid
unoccupi
occupi
glycan
method
workflow
includ
proteas
treatment
sequenti
glycosidas
digest
first
treat
endo
h
digest
pngase
f
follow
analysi
figur
author
determin
almost
glycan
site
occupi
solubl
env
trimer
report
method
potenti
serv
robust
tool
facilit
ration
design
develop
vaccin
two
subtyp
c
env
current
evalu
pivot
phase
iibiii
efficaci
trial
south
africa
assess
hiv
infect
among
adult
prevent
trial
design
confirm
extend
partial
protect
seen
infect
thai
trial
http
wwwniaidnihgovnewseventsfirstnewhivvaccineefficacystudysevenyearshasbegun
wang
et
al
carri
extens
character
vaccin
antigen
refer
standard
repres
materi
equival
cgmp
materi
confirm
sequenc
integr
biophys
immunogen
glycosyl
pattern
disulfid
linkag
data
report
demonstr
immunogen
antigen
provid
comprehens
character
molecul
set
benchmark
assess
current
futur
ctm
lot
establish
physicochem
groundwork
interpret
futur
clinic
trial
exampl
applic
method
trimer
env
glycoprotein
commerci
manufactur
current
good
manufactur
practic
cgmp
analyz
use
hybrid
linear
trapfouri
transform
ion
cyclotron
reson
fticr
mass
spectromet
coupl
water
nanoacqu
uplc
system
vaccin
candid
cgmp
produc
bioreactor
extens
character
molecular
structur
disulfid
bond
pattern
glycosyl
profil
first
report
trimer
hiv
vaccin
clinic
trial
materi
produc
cgmp
condit
comprehens
character
use
mass
spectrometri
method
report
studi
pave
way
cgmp
product
env
glycoprotein
trimer
variou
ms
instrument
deciph
structur
complex
glycoprotein
develop
test
hiv
vaccin
exemplifi
base
structur
character
method
provid
complementari
inform
routin
use
analyt
method
batch
releas
test
refin
env
structur
vaccin
design
influenza
viru
segment
envelop
rna
viru
among
virul
pathogen
within
influenza
viru
famili
three
genera
b
c
influenza
virus
subtyp
accord
surfac
antigen
haemagglutinin
ha
neuraminidas
na
ha
subtyp
na
subtyp
identifi
date
mani
differ
combin
ha
na
possibl
http
wwwcdcgovfluavianfluinfluenzaavirussubtypeshtm
vaccin
influenza
viru
effect
mean
prevent
sinc
influenza
vaccin
use
prevent
tool
flu
season
world
health
organ
recommend
develop
influenza
vaccin
sinc
number
mammalian
cell
line
evalu
manufactur
influenza
fda
approv
first
cell
influenza
vaccin
flucelvax
novarti
vaccin
fda
approv
flublok
protein
scienc
corpor
first
licens
recombin
vaccin
use
insect
viru
express
system
http
wwwcdcgovfluprotectvaccinevaccineshtm
season
epidem
worldwid
popul
typic
infect
result
million
case
sever
ill
death
per
year
http
unpredict
associ
strain
influenza
viru
circul
due
antigen
drift
frequent
mutat
viral
protein
address
strain
select
made
annual
ensur
immunodiffus
srid
approv
method
measur
content
hemagglutinin
ha
inactiv
influenza
vaccin
srid
method
quantifi
ha
content
influenza
vaccin
reli
refer
reagent
avail
may
caus
delay
formul
influenza
vaccin
especi
pandem
outbreak
workshop
organ
ottawa
canada
decid
explor
altern
approach
quantif
ha
content
speed
vaccin
deliveri
process
futur
respons
pandem
influenza
season
vaccin
variou
promis
method
altern
srid
assay
current
develop
includ
hplc
ms
primari
object
method
use
perform
quantit
without
refer
standard
thu
formul
viru
strain
without
delay
owe
refer
reagent
proteom
method
measur
ha
strain
content
develop
center
vaccin
evalu
cve
canada
nation
center
environment
health
nceh
center
diseas
control
prevent
cdc
unit
state
method
develop
use
qualiti
control
lab
simultan
identifi
three
four
differ
viru
strain
measur
strain
influenza
vaccin
research
specif
work
evalu
isotop
dilut
mass
spectrometri
idm
method
accur
quantit
ha
primari
influenza
standard
sinc
method
involv
isotop
dilut
mass
spectrometri
idm
conjunct
multipl
reaction
monitor
mrm
appli
detect
target
peptid
use
isotop
label
peptid
standard
absolut
quantif
ha
subtyp
influenza
vaccin
figur
assay
applic
trival
matric
use
without
sampl
cleanup
presenc
deterg
protein
importantli
idm
method
perform
without
use
viru
refer
standard
quantif
ha
avian
influenza
vaccin
howev
direct
comparison
result
obtain
obtain
srid
spring
chines
health
famili
plan
commiss
notifi
first
confirm
human
infect
avian
influenza
viru
develop
quantifi
ha
na
influenza
use
analyz
sampl
confirm
separ
studi
ha
antigen
yield
vaccin
strain
also
determin
use
research
also
demonstr
uniqu
quantif
immunoreact
viral
influenza
protein
immunoaffin
captur
follow
method
truli
altern
approv
srid
method
dual
purpos
potenc
content
determin
found
equival
srid
method
also
use
respons
pandem
influenza
addit
direct
liquid
chromatographi
uplc
method
report
rapid
accur
quantif
influenza
method
also
report
simultan
identif
quantif
ha
na
influenza
vaccin
sampl
analyz
water
synapt
mass
quantif
protein
power
tool
method
altern
scan
low
collis
energi
elev
collis
energi
analysi
obtain
protein
ident
quantiti
singl
experi
quantif
base
experiment
data
show
signal
intens
proport
concentr
allow
amount
protein
mixtur
estim
util
parallel
multiplex
fragment
peptid
precursor
simultan
fragment
throughout
chromatograph
separ
process
regardless
intens
allow
identif
lower
abund
peptid
provid
increas
proteom
coverag
dynam
rang
protein
quantif
compar
research
center
vaccin
valuat
cve
canada
concurr
work
develop
method
measur
ha
content
influenza
vaccin
develop
number
hplc
method
et
al
report
method
combin
sec
hplc
effect
separ
subtyp
ha
antigen
trival
vaccin
base
differ
elut
profil
howev
method
need
antigen
refer
standard
quantit
ha
cve
research
also
report
method
simultan
absolut
quantif
ha
na
level
commerci
influenza
vaccin
separ
antigen
identifi
enzymat
digest
follow
recent
fast
highli
select
method
determin
ha
content
quadrival
influenza
vaccin
hplc
report
hplc
method
show
excel
resolut
four
hemagglutinin
also
physicochem
method
capabl
distinguish
b
strain
quadrival
influenza
eluent
use
hplc
method
vv
aqueou
trifluoroacet
acid
tfa
vv
tfa
acn
condit
develop
method
could
easili
implement
onlin
method
speed
data
collect
gain
addit
structur
inform
separ
ha
antigen
srid
assay
use
year
quantit
potenc
method
throughout
world
despit
issu
regard
variabl
avail
standard
reagent
thu
even
though
new
method
like
hplc
mass
spectrometri
develop
take
time
method
adopt
worldwid
next
influenza
pandem
predict
health
author
pandem
prepared
effort
includ
effort
ensur
expedit
avail
pandem
vaccin
method
hplc
ms
abil
quantit
antigen
without
standard
refer
reagent
becom
cornerston
pandem
influenza
prepared
viral
genu
flaviviru
includ
dengu
viru
yellow
fever
viru
zika
viru
dengu
repres
common
diseas
human
caus
million
case
infect
hospit
death
estim
occur
world
first
dengu
vaccin
dengvaxia
develop
sanofi
pasteur
live
attenu
tetraval
chimer
vaccin
made
use
recombin
dna
technolog
tetraval
dengu
vaccin
produc
mammalian
vero
cell
consist
four
chimer
virus
env
protein
dengvaxia
releas
pngase
f
deglycosyl
purifi
measur
ms
posit
ioniz
mode
use
acid
matrix
detect
ion
singli
charg
sodium
adduct
monoisotop
mass
glycan
env
protein
found
mix
hybrid
complex
glycan
figur
analysi
dengvaxia
use
demonstr
asparagin
residu
glycosyl
predomin
high
mainli
combin
studi
provid
import
new
insight
role
glycan
dengu
cell
interact
separ
studi
accur
quantit
express
four
viral
particl
tetraval
dengu
vaccin
cyd
perform
use
target
ms
select
reaction
monitor
srm
studi
describ
orthogon
quantit
strategi
target
ms
srm
mode
demonstr
variabl
ms
method
low
assay
linear
nmoll
base
report
method
perform
could
use
releas
futur
batch
tetraval
dengu
vaccin
ebola
hemorrhag
fever
one
fatal
viral
diseas
worldwid
ebola
outbreak
caus
case
infect
death
year
quest
effect
vaccin
ebola
viru
infect
continu
present
number
vaccin
candid
explor
multipl
experiment
clinic
trial
ongo
evid
util
ms
import
tool
vaccin
develop
recent
use
character
emerg
ebola
vaccin
one
studi
glycan
identif
transmembran
glycoprotein
solubl
glycoprotein
sgp
ebola
viru
express
human
embryon
kidney
cell
ebov
yambuku
perform
hplc
ms
neg
ion
result
show
glycan
complex
sialyl
primarili
recent
comprehens
character
glycosyl
carri
glycosyl
pattern
five
pathogen
ebola
virus
bdbv
sudv
tafv
two
ebov
variant
produc
mammalian
cell
data
present
demonstr
pattern
similar
pattern
remark
differ
five
ebola
virus
studi
serv
foundat
futur
ebola
viral
entri
immunogen
improv
convent
approach
absolut
quantit
ebola
particl
evlp
isotop
dilut
liquid
mass
spectrometri
method
develop
use
ultim
hplc
orbitrap
elit
hybrid
ion
mass
report
ms
quantit
method
provid
mean
rapidli
determin
evlp
batch
qualiti
base
upon
quantit
antigen
also
ensur
adequ
preclinicalclin
dose
chikungunya
viral
diseas
endem
africa
southeast
asia
also
recent
emerg
caribbean
current
drug
vaccin
avail
treatment
prevent
name
chikungunya
deriv
makond
word
mean
becom
contort
describ
stoop
appear
suffer
joint
pain
arthralgia
continu
effort
develop
vaccin
chikungunya
current
clinic
trial
experiment
vaccin
prevent
infect
chikungunya
viru
method
use
character
experiment
chikungunya
chikv
particl
vlp
vaccin
one
studi
method
develop
separ
capsid
protein
chikv
vlp
vaccin
good
resolut
separ
protein
compon
verifi
ms
studi
modif
viral
glycoprotein
identifi
intact
protein
mass
measur
method
use
addit
character
ptm
monitor
product
puriti
process
develop
assess
product
stabil
formul
anoth
studi
hilic
lc
method
fluoresc
ms
detect
perform
character
pattern
chikv
vlp
develop
method
use
monitor
glycosyl
chikv
vlp
vaccin
process
develop
ensur
batch
neisseria
meningitid
meningococcu
bacterium
caus
mening
form
meningococc
diseas
meningococcemia
sepsi
two
type
vaccin
protect
meningococc
diseas
meningococc
conjug
vaccin
quadrival
vaccin
serogroup
c
serogroup
b
meningococc
vaccin
approach
use
perform
physicochem
character
one
studi
research
use
character
glycosyl
lysin
residu
anoth
studi
method
use
determin
rel
reactiv
lysin
residu
determin
amino
acid
suscept
also
use
quantifi
vaccin
first
vaccin
develop
revers
vaccinolog
approach
vaccin
tani
et
al
use
methodolog
perform
quantif
outer
membran
vesicl
protein
vaccin
approach
use
intens
ms
signal
respons
three
intens
tryptic
peptid
perform
absolut
three
recombin
protein
vaccin
activ
compon
methodolog
use
qualit
quantit
character
three
protein
ms
method
perform
addit
character
addit
standard
qualiti
control
test
vaccin
batch
also
vaccin
compos
two
factor
h
bind
protein
fhbp
variant
recombinantli
express
e
coli
nativ
lipoprotein
ga
spectrometri
gcm
liquid
spectrometri
lcm
use
analyz
composit
fatti
acid
releas
complet
character
primari
structur
recombin
lipoprotein
analysi
carri
use
acquiti
uhplcuv
system
interfac
electrospray
ioniz
quadrupol
mass
spectromet
bruker
dalton
maxi
innovax
first
vaccin
hepat
e
viru
hev
obtain
e
coli
licens
fda
china
vlp
vaccin
consist
truncat
recombin
hev
capsid
protein
express
e
coli
spontan
form
vlp
particl
nm
sever
analyt
method
includ
peptid
map
employ
examin
qualiti
size
stabil
protein
compris
vlp
vaccin
ensur
consist
term
size
qualiti
multipl
batch
commerci
scale
contain
vlp
character
size
exclus
chromatographi
human
papillomaviru
hpv
type
vaccin
licens
hpv
infect
caus
develop
cervic
cancer
second
common
caus
death
women
worldwid
although
multipl
type
hpv
lead
cervic
cancer
human
type
respons
peptid
map
perform
confirm
primari
sequenc
recombin
protein
major
antigen
protein
capsid
hpv
type
peptid
sequenc
coverag
observ
hpv
vlp
addit
one
modif
acetyl
also
identifi
li
viral
protein
within
vlp
peptid
map
use
verifi
batch
batch
consist
identifi
modif
occur
protein
express
therapeut
vaccin
current
approv
use
human
nipah
viru
niv
emerg
highli
pathogen
zoonot
viru
paramyxoviridia
famili
solubl
glycoprotein
viru
vector
platform
develop
protect
niv
sporad
natur
niv
outbreak
make
larg
scale
phase
iii
clinic
trial
difficult
interest
recent
applic
ms
field
vaccin
et
al
quantifi
viral
f
g
protein
present
viral
particl
also
analyz
cellular
proteom
composit
niv
vaccin
candid
tradit
viral
particl
describ
pure
entiti
carri
protein
author
success
analyz
ratio
cellular
viral
protein
niv
vaccin
candid
use
west
nile
fever
flaviviru
caus
viral
infect
typic
spread
mosquito
date
vaccin
avail
prevent
west
nile
infect
partial
purifi
particl
resolv
coomassi
band
correspond
env
protein
excis
gel
destain
analyz
ms
microcapillari
perform
use
lcq
deca
mass
spectromet
thermo
finnigan
identifi
presenc
env
protein
particl
help
develop
potenti
decemb
china
food
drug
administr
approv
two
inactiv
vaccin
prevent
sever
hfmd
hand
foot
mouth
diseas
peptid
map
sequenc
perform
use
mass
spectromet
molecular
weight
capsid
protein
vlp
determin
use
ms
proteom
analyz
appli
biosystem
framingham
ms
techniqu
choic
identif
structur
character
tremend
complex
glycoprotein
routin
use
tool
earli
research
develop
molecul
implement
ms
method
chemistri
manufactur
control
cmc
qualiti
control
environ
vaccin
longstand
interest
face
regulatori
challeng
best
knowledg
author
awar
releas
method
use
vaccin
product
qualiti
controlcgmp
environ
alway
reluct
implement
new
method
qualiti
controlcgmp
environ
case
ms
multipl
misconcept
regard
techniqu
although
ms
without
limit
misconcept
relat
reproduc
valid
overst
implement
method
qc
environ
method
valid
demonstr
method
accuraci
precis
intermedi
precis
specif
linear
limit
detect
limit
quantit
furthermor
appropri
system
suitabl
control
calibr
part
method
ensur
repeat
paramet
control
ensur
perform
assay
variabl
differ
instrument
oper
aris
unfortun
aspect
valid
activ
inher
challeng
method
thu
burden
proof
lie
vaccin
develop
convinc
regul
method
phase
appropri
releas
test
without
regulatori
guidelin
applic
class
drug
clear
author
perspect
classic
valid
regul
state
ich
guidelin
unsuit
method
last
decad
convent
releas
assay
replac
hplc
capillari
electrophoresi
ce
method
qc
environ
assay
use
monitor
aggreg
fragment
clip
content
determin
applic
ms
vaccin
qc
environ
evolv
stori
challeng
convinc
regul
direct
toward
highlight
ms
capabl
shown
multipl
exampl
manuscript
work
field
import
present
ms
data
test
multipl
qualiti
attribut
sampl
analyt
run
combin
hplcce
method
perform
ms
analysi
valid
simpler
hpuplc
assay
use
assess
batch
batch
consist
way
compar
data
set
could
demonstr
author
believ
ultim
util
method
qc
releas
vaccin
main
ration
method
qccgmp
environ
replac
exist
method
rather
supplement
batch
releas
test
ensur
product
within
specif
without
unwarr
modif
use
ms
techniqu
ensur
improv
qualiti
increas
safeti
clinic
trial
particip
conclus
evid
suggest
emerg
techniqu
advanc
field
vaccin
develop
lc
coupl
ms
repres
power
character
tool
vaccin
develop
especi
recombinantli
produc
antigen
techniqu
rapidli
use
quantit
vaccin
antigen
explor
molecular
structur
also
comprehens
analysi
glycan
import
question
remain
establish
ms
techniqu
qualiti
control
cgmp
lab
vaccin
releas
given
wide
use
classic
method
lack
regulatori
guidanc
nevertheless
decad
steadi
partnership
vaccin
develop
ms
expand
nich
applic
enabl
platform
vaccin
develop
